David A. Siegel Erasca, Inc. Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Erasca, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 343,100 shares of ERAS stock, worth $538,667. This represents 0.0% of its overall portfolio holdings.

Number of Shares

343,100

Previous 594,600 42.3%

Holding current value

$538,667

Previous $1.49 Million 68.5%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.28 - $2.75 $321,920 - $691,625	-251,500 Reduced 42.3%	343,100 $470,000
Q4 2024 Feb 14, 2025	SELL	$2.44 - $3.23 $484,584 - $641,478	-198,600 Reduced 25.04%	594,600 $1.49 Million
Q3 2024 Nov 14, 2024	SELL	$2.17 - $3.28 $108,717 - $164,328	-50,100 Reduced 5.94%	793,200 $2.17 Million
Q2 2024 Aug 14, 2024	SELL	$1.79 - $2.63 $344,754 - $506,538	-192,600 Reduced 18.59%	843,300 $1.99 Million
Q1 2024 May 15, 2024	BUY	$1.67 - $2.55 $683,698 - $1.04 Million	409,400 Added 65.35%	1,035,900 $2.13 Million
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.49 $223,613 - $333,411	133,900 Added 27.18%	626,500 $1.33 Million
Q3 2023 Nov 14, 2023	SELL	$1.97 - $2.91 $297,076 - $438,828	-150,800 Reduced 23.44%	492,600 $970,000
Q2 2023 Aug 14, 2023	BUY	$2.57 - $3.3 $547,924 - $703,560	213,200 Added 49.56%	643,400 $1.78 Million
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $1.08 Million - $1.75 Million	394,600 Added 1108.43%	430,200 $1.29 Million
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $138,484 - $305,092	35,600 New	35,600 $153,000

Others Institutions Holding ERAS

# of Institutions

162

Shares Held

222M

Call Options Held

20.6K

Put Options Held

5.7K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $192M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account